Comparative in vitro activity of the new oral cephalosporin BMY-28100.

Using a broth microdilution method, the in vitro activity of BMY-28100 against 365 clinical strains of commonly isolated bacteria was determined. BMY-28100 showed good activity against streptococci, methicillin-susceptible staphylococci, Salmonella spp., Shigella spp., and beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Against susceptible strains of these organisms, BMY-28100 showed activity comparable to that of penicillin G, ampicillin, co-trimoxazole, erythromycin, cefaclor, doxycycline and amoxicillin/potassium clavulanate. BMY-28100 had moderate activity against Arizona hinshawii and poor activity against Campylobacter jejuni and Yersinia enterocolitica.